Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report

RATIONALE: Immunotherapy and targeted therapy have attracted widespread attention in current clinical research, which could be considered as a good therapeutic option for treatment of refractory liver cancer. PATIENT CONCERNS: The patient was a 37-year-old man with hepatitis B virus (HBV) infection....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Fengjiao, Zhou, Yong, Seesaha, Poshita Kumari, Zhang, Yihong, Liu, Siqin, Gan, Xiaoyan, Hu, Jun, Gu, Yanhong, Chen, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505406/
https://www.ncbi.nlm.nih.gov/pubmed/32957395
http://dx.doi.org/10.1097/MD.0000000000022312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505406/
https://www.ncbi.nlm.nih.gov/pubmed/32957395
http://dx.doi.org/10.1097/MD.0000000000022312

Ejemplares similares